Significance: Real-time histology can close a variety of gaps in tissue diagnostics. Currently, gross pathology analysis of excised tissue is dependent upon visual inspection and palpation to identify regions of interest for histopathological processing. Such analysis is limited by the variable correlation between macroscopic and microscopic findings. The current standard of care is costly, burdensome, and inefficient.Aim: We are the first to address this gap by introducing optical coherence tomography (OCT) to be integrated in real-time during the pathology grossing process.Approach: This is achieved by our high-resolution, ultrahigh-speed, large field-of-view OCT device designed for this clinical application.Results: We demonstrate the feasibility of imaging tissue sections from multiple human organs (breast, prostate, lung, and pancreas) in a clinical gross pathology setting without interrupting standard workflows.Conclusions: OCT-based real-time histology evaluation holds promise for addressing a gap that has been present for >100 years.
Optical coherence tomography (OCT) is being studied to provide rapid biopsy evaluation. Here we developed a deep learning algorithm to rapidly identify disease in OCT images in an 87-patient IRB-approved clinical study. Pathologists labelled each biopsy into two categories: non-interest (no disease) and interest (for further pathological analysis). Our dataset was split by patients into training (n = 70) and validation (n = 17). The Resnet18 architecture used the Adam optimizer, had a learning rate of 0.01, batch size of 8, and ran for 30 epochs. The network achieved 97% training accuracy and 70% validation accuracy.
This Conference Presentation, Real-time histology evaluation by optical coherence tomography (OCT) holds promise to improve the diagnostic anatomic pathology gross evaluation process, was recorded at SPIE Photonics West held in San Francisco, California, United States.
In this retrospective study, we evaluated imaging data from 65 breast cancer patients that were obtained one to three days before the initiation of neoadjuvant chemotherapy (NAC). Imaging was performed with a dynamic optical tomography breast imaging system (DOTBIS) over the course of a breath hold. From this imaging data, we extracted time-dependent signal traces of the total hemoglobin in the whole volume of the tumor-bearing breast. The inflection point and the slope at the steepest part of the curve were calculated for both the ascending (patient holds her breath) and descending slopes (patient releases her breath and starts breathing normally again). Our results show statistically significant differences in vascular changes between patients with a pathologic complete response (pCR) and non-pCR patients. This suggests that differences in the tumor-bearing breasts of these two patient groups exist even before treatment is started.
This work evaluates changes in features of 3D breast images generated by a so-called dynamic optical tomographic imaging system (DOTBIS) during neoadjuvant chemotherapy (NAC). Images from 23 breast cancer patients were analyzes and correlated with respect to treatment outcome and status of hormone receptors and human epidermal growth factor receptors. Our data shows that the ratio of the mean value of deoxy-hemoglobin (ctHHbN) at two weeks after the first treatment compared to baseline was statistically significantly lower in patients that achieve a pathologic complete response (pCR) (0.77 ± 0.22) as compared to patients with a non-pCR (1.14 ± 0.24, P < .005). These observations indicate that early changes in DOTBIS images can potentially be used to predict breast cancer response to NAC and may allow a better way to customize therapy to HR+/HER2- patients in order to optimize treatment.
Optical imaging techniques have emerged as a possible alternative to predict pathological complete response (pCR) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). Our team developed a so-called diffuse optical tomographic breast imaging system (DOTBIS) which does not require the use of contrast agents or compression and enables imaging of the whole breast volume using low intensity near infrared light capable to measure tissue concentration of total hemoglobin (ctTHb). In this retrospective study, we evaluated 55 stage II-III BC patients in the neoadjuvant setting who received weekly paclitaxel x 12, followed by dose-dense adriamycin/cyclophosphamide every 2 weeks x 4. DOTBIS images were acquired from the patient whole breast volume at 6 different time points: at baseline (TP0); two weeks after the first taxane infusion (TP1); after four infusions of taxane (TP2); at the end of the taxane regimen and before starting AC cycle (TP3); after two AC infusions (TP4); and at the end of NAC and before surgery (TP5). In order to evaluate whether pCR status influences the change of ctTHb over time, we designed a multilevel mixed-effect model. pCR was defined as no invasive tumor cells from the breast and axillary tissue at surgery (ypT0 ypN0). Changes in ctTHb levels compared to baseline (TP0) values were statistically significant different between pCR (n = 20) and non-pCR (n=35) at all time points except at TP1 and at the end of the taxane cycle (TP3).
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.